CD47:对于非小细胞肺癌的免疫检查点封锁的下一个前沿
Asa P Y Lau1,2, Sharon S Khavkine Binstock1,2, Kelsie L Thu1,2
1Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Cancers
|November 14, 2023
概括
CD47阻断是肺癌的有希望的免疫疗法,特别是在对PD-1抑制剂无反应的患者中. 准CD47-SIRPα轴可以克服免疫逃避并改善肺癌患者的生存率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 编程细胞死亡蛋白1 (PD-1) 和其连接体 (PD-L1) 疗法已在肺癌中取得成功.
- 然而,许多患者对PD-1阻塞没有反应或不符合条件.
- CD47是一种免疫抑制分子,在肺癌中被上调,并与预后不佳有关,特别是在对PD-1治疗有抗性的EGFR突变瘤中.
研究的目的:
- 审查CD47-SIRPα轴在肺癌免疫规避中的作用.
- 讨论目前和新兴的CD47向策略,用于肺癌免疫疗法.
- 评估CD47阻断作为潜在的下一代肺癌治疗方法.
主要方法:
- 关于癌症免疫循环和免疫检查点的文献综述.
- 对肺癌中CD47表达的分析及其与生存率和突变的相关性.
- 审查已批准的免疫检查点抑制剂和正在进行的针对CD47的临床试验.
主要成果:
- 瘤破坏癌症免疫循环,利用CD47-SIRPα等免疫检查点进行免疫逃避.
- CD47表达与肺癌的生存率低下有关,特别是在EGFR突变瘤中.
- 几种针对CD47的药物正在临床开发中,用于肺癌.
结论:
- CD47阻断代表了一个有希望的下一代免疫疗法用于肺癌.
- 针对CD47-SIRPα轴可以克服先天性免疫检查点并增强抗瘤免疫力.
- 克服CD47阻断开发中的障碍对于将其确立为标准肺癌疗法至关重要.
相关概念视频
01:27Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K